Text Size
43 studies found for:    regeneron | Open Studies

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Study of REGN727 (SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin);   Drug: REGN727 (SAR236553);   Other: Placebo
2 Recruiting Study of REGN727 (SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (Odyssey Alternative)
Condition: Hypercholesterolemia
Interventions: Drug: REGN727 (SAR236553);   Drug: Active Comparator 1 (ezetimibe);   Drug: Active Comparator 2 (atorvastatin);   Other: Placebo 1 (placebo for ezetimibe atorvastatin);   Other: Placebo 2 [(placebo for REGN727 (SAR236553]
3 Recruiting Study of the Efficacy and Safety of REGN727 (SAR236553) in Combination With Other Lipid-modifying Treatments (LMT)
Condition: Hypercholesterolemia
Interventions: Drug: REGN727 (SAR236553);   Drug: Atorvastatin;   Drug: Ezetimibe;   Drug: Rosuvastatin;   Other: Placebo
4 Recruiting Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
Condition: Age - Related Macular Degeneration (AMD)
Intervention: Drug: Intravitreal Aflibercept Injection (IAI)
5 Recruiting Study of REGN727 (SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT)
Condition: Hypercholesterolemia
Interventions: Drug: REGN727 (SAR236553);   Other: Placebo;   Drug: Rosuvastatin;   Drug: Ezetimibe
6 Recruiting A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: REGN421(SAR153192)
7 Recruiting REGN910 (SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Condition: Solid Tumors
Interventions: Drug: REGN910 (SAR307746);   Drug: aflibercept (ziv-aflibercept)
8 Recruiting Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Condition: Cancer
Interventions: Drug: REGN1400;   Drug: Erlotinib;   Drug: Cetuximab
9 Recruiting Study of REGN910 (SAR307746)
Condition: Solid Tumors
Intervention: Drug: REGN910 (SAR307746)
10 Recruiting Study to Assess the Safety and Tolerability of Single Doses of REGN1500
Condition: Healthy Volunteers
Interventions: Drug: REGN1500;   Drug: Placebo
11 Recruiting The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Intervention: Drug: Intravitreal Aflibercept Injection
12 Recruiting Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: Intravitreal injection of Aflibercept
13 Recruiting Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)
Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727);   Other: placebo
14 Recruiting Efficacy and Safety Evaluation of SAR236553 (REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab SAR236553 (REGN727);   Drug: placebo;   Drug: atorvastatin
15 Recruiting Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
Condition: Fibrovascular Pigment Epithelial Detachment
Intervention: Drug: Aflibercept
16 Recruiting VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
Condition: Macular Degeneration
Interventions: Biological: VEGF Trap-Eye (BAY86-5321);   Drug: Visudyne
17 Recruiting Efficacy and Safety of SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727);   Other: placebo
18 Available Use of Eylea for the Treatment of an Optic Nerve Hemangioma
Condition: Retinal Hemangioma
Intervention: Drug: Aflibercept
19 Recruiting IL1-TRAP, Rilonacept, in Systemic Sclerosis
Conditions: Scleroderma;   Systemic Sclerosis;   Diffuse Scleroderma;   Diffuse Systemic Sclerosis
Interventions: Drug: Rilonacept;   Drug: Placebo
20 Recruiting Colorectal Cancer Metastatic
Condition: Colorectal Cancer Metastatic
Interventions: Drug: AFLIBERCEPT AVE0005;   Drug: irinotecan;   Drug: fluorouracil;   Drug: Leucovorin
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years